Novartis, the third largest pharmaceutical company, have come to an agreement with Cigna and Aetna for a performance-based price for its heart failure drug, Entresto. Michael Billings, a Novartis spokesperson, “Novartis will reduce the price of Entresto to payers, if the rate of heart failure hospitalization of patients on Entresto exceed a pre-specified threshold …patients need access to innovative medicines, and we are committed to doing our part.” Read article here…..
Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.